Biofrontera Inc. (BFRI)
1.04
-0.09 (-7.96%)
At close: Jan 14, 2025, 3:59 PM
1.04
-0.48%
After-hours Jan 14, 2025, 06:44 PM EST
undefined% (undefined)
| Bid | 0.98 |
| Market Cap | 8.10M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.16 |
| PE Ratio (ttm) | 0.9 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.05 |
| Volume | 258,188 |
| Avg. Volume (20D) | 3,190,157 |
| Open | 1.14 |
| Previous Close | 1.13 |
| Day's Range | 1.02 - 1.14 |
| 52-Week Range | 0.61 - 2.43 |
| Beta | undefined |
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-m...
Sector Healthcare
IPO Date Oct 29, 2021
Employees 83
Stock Exchange NASDAQ
Ticker Symbol BFRI
Website https://www.biofrontera.us.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BFRI stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 569.86% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Biofrontera Inc. is scheduled to release its earnings on Mar 14, 2025,
during market hours.
Analysts project revenue of $14.05M, reflecting a 32.61% YoY growth and earnings per share of -0.07, making a -104.24% decrease YoY.
Analysts project revenue of $14.05M, reflecting a 32.61% YoY growth and earnings per share of -0.07, making a -104.24% decrease YoY.
6 days ago ·
Source
+6.31%
Biofrontera shares are trading higher after the co...
Unlock content with
Pro Subscription
2 months ago ·
Source
-15.38%
Biofrontera shares are trading lower after the company reported worse-than-expected Q3 financial results.
